OncoPharm

An exciting new cellular therapy, lifileucel, is approved for metastatic melanoma. The FLAURA2 trial of osimertinib + chemotherapy has led to an FDA approval, but questions remain about a possible new standard of care. And a few minor updates on tepotinib.

New updates on metastatic pancreatic cancer (NAPOLI-3), upper tract urothelial cancer (POUT), and the drug-drug interaction between ivosidenib and azole antifungals.

NAPOLI 3: https://doi.org/10.1016/S0140-6736(23)01366-1

POUT (final OS): https://doi.org/10.1200/JCO.23.01659

Ivosidenib Azole Antifungal DDIs: https://doi.org/10.1002/cncr.35251

You know about small cell lung cancer, but let's talk about small cell carcinoma of the prostate.

In oncology we are always asking questions about which treatment option is best. And that focus on the next best treatment may prevent us from rethinking some fundamentals of current practice. Three recent studies illustrate this and made me ask:

Do we need a Port or PICC for every testicular cancer patient?

Study: https://doi.org/10.1200/OP.23.00580

Editorial: https://doi.org/10.1200/OP.23.00730

Is vaginal estrogen safe if breast cancer patients?

Study: https://jamanetwork.com/journals/jamaoncology/article-abstract/2811413

Does paclitaxel work differently than we always thought?

Study: https://doi.org/10.1371/journal.pbio.3002339

...on FDA approvals for belzutifan for RCC, pembrolizumab + cisplatin/RT for cervical cancer, erdafitinib (FGFR3 alterations only) for bladder cancer.

Plus, early morning ICIs (https://doi.org/10.1016/j.ejca.2024.113571)

&

FLAG-Ida-GO in AML from NCRI AML 19 (https://doi.org/10.1200/JCO.23.00943)

Special guest Ryan Beechinor joins the pod to discuss his recent paper on the obstacles in the development of generic lenalidomide. It's a fantastic read, and this episode will be a fantastic listen!

Link: https://doi.org/10.1016/j.jcpo.2023.100446

Foundations of OncoPharm episode on lenalidomide (Revlimid) and its MOA, use, dosing, & toxicity.

A Holiday Tradition returns as we review 14 new OncoPharm drugs approved this past year and ask Keep, Re-Gift, or Return.

Small bites of updates coming out of ASH's 2023 annual meeting on CLL, multiple myeloma, and lymphoma.

Our Landmarks of OncoPharm series returns to talk about 2008's VISTA study, which ushered bortezomib into the front line setting, albeit with a now outdated alkylating agent-based backbone.

VISTA (VMP vs. MP): https://www.nejm.org/doi/full/10.1056/nejmoa0801479